- |||||||||| Enrollment closed, Trial completion date, Trial primary completion date: EC-02: The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma (clinicaltrials.gov) - May 9, 2023
P=N/A, N=240, Active, not recruiting, N=300 --> 0 | Completed --> Withdrawn Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2020 --> Dec 2023
- |||||||||| TroVax (MVA 5T4) / Oxford Biomedica
Trial completion: TRIOC: The Activity of TroVax (clinicaltrials.gov) - May 9, 2019 P2, N=94, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| defactinib (VS-6063) / Verastem
Trial termination, Combination therapy: Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer (clinicaltrials.gov) - Apr 30, 2019 P1, N=98, Terminated, Active, not recruiting --> Completed Active, not recruiting --> Terminated; The study was terminated upon completion of escalation phase, prior to opening expansion cohorts
- |||||||||| Enrollment change, Trial completion date, Trial primary completion date: Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) (clinicaltrials.gov) - Apr 29, 2019
P=N/A, N=500, Recruiting, Active, not recruiting --> Terminated; The study was terminated upon completion of escalation phase, prior to opening expansion cohorts N=100 --> 500 | Trial completion date: Dec 2020 --> Dec 2025 | Trial primary completion date: Dec 2020 --> Dec 2025
- |||||||||| Trial completion: C (clinicaltrials.gov) - Apr 24, 2019
P=N/A, N=900, Completed, Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018 Active, not recruiting --> Completed
- |||||||||| topotecan / Generic mfg., carboplatin / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 20, 2019 P1, N=48, Completed, Phase classification: P1/2 --> P=N/A Active, not recruiting --> Completed
- |||||||||| Preclinical, Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Clinical Effectiveness of Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer (clinicaltrials.gov) - Apr 18, 2019
P=N/A, N=138, Terminated, Active, not recruiting --> Completed N=800 --> 138 | Trial completion date: Dec 2020 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Dec 2018; very slow recruitment
- |||||||||| Trial completion: Hula, a Physical Activity Intervention for Female-Cancer Survivors (clinicaltrials.gov) - Apr 18, 2019
P=N/A, N=73, Completed, N=800 --> 138 | Trial completion date: Dec 2020 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Dec 2018; very slow recruitment Active, not recruiting --> Completed
- |||||||||| Trial completion, Trial completion date, Trial primary completion date, Surgery: Surgicel Reduces Ovarian Endometriomas Recurrence (clinicaltrials.gov) - Apr 16, 2019
P2, N=200, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Apr 2018 --> Jan 2019 | Trial primary completion date: Apr 2018 --> Jan 2019
- |||||||||| Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine, Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
Trial completion, Enrollment change: CoheaHr-WP4: Comparing Health Services Interventions for the Prevention of HPV-related Cancer (clinicaltrials.gov) - Apr 10, 2019 P4, N=63, Completed, Recruiting --> Completed | Trial completion date: Apr 2018 --> Jan 2019 | Trial primary completion date: Apr 2018 --> Jan 2019 Recruiting --> Completed | N=300 --> 63
- |||||||||| Trial completion, Trial primary completion date: EnMotion, Embryo's Natural Motion (clinicaltrials.gov) - Apr 5, 2019
P=N/A, N=200, Completed, Recruiting --> Completed | N=300 --> 63 Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> May 2018
- |||||||||| CRS-207 / Novartis
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: SEASCAPE: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer (clinicaltrials.gov) - Apr 4, 2019 P1/2, N=35, Terminated, Recruiting --> Terminated; Terminated due to difficult recruitment N=126 --> 35 | Trial completion date: Dec 2018 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Apr 2018; Study was stopped due to low enrollment and lack of clinical activity.
- |||||||||| Trial completion, Phase classification, Trial completion date, Trial primary completion date: ULMOST: Ultrasonic Versus Monopolar Energy-based Surgical Device in Colpotomy (clinicaltrials.gov) - Apr 3, 2019
P=N/A, N=40, Completed, N=126 --> 35 | Trial completion date: Dec 2018 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Apr 2018; Study was stopped due to low enrollment and lack of clinical activity. Recruiting --> Completed | Phase classification: P3 --> PN/A | Trial completion date: Apr 2018 --> Apr 2017 | Trial primary completion date: Apr 2018 --> Apr 2017
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) - Apr 2, 2019
P=N/A, N=23, Terminated, Recruiting --> Completed | Phase classification: P3 --> PN/A | Trial completion date: Apr 2018 --> Apr 2017 | Trial primary completion date: Apr 2018 --> Apr 2017 N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data.
- |||||||||| Menopur (menotropin) / Ferring
Trial completion, Enrollment change: A Study on Efficacy and Safety of Menopur® Multidose in Korean Female Patients With Infertility (clinicaltrials.gov) - Mar 28, 2019 P=N/A, N=412, Completed, N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. Recruiting --> Completed | N=2002 --> 412
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Trial completion date: TNFSF11 Inhibition and Fertility: a Prospective Study (clinicaltrials.gov) - Mar 27, 2019 P2, N=12, Completed, Recruiting --> Completed | N=2002 --> 412 Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2019
- |||||||||| Trial completion, Trial primary completion date: Clinical Tests to Predict the Success of Assisted Reproductive Techniques (clinicaltrials.gov) - Mar 26, 2019
P=N/A, N=542, Completed, Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2019 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Oct 2018
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Sentinel Lymph Node Detection in Endometrial Cancer (clinicaltrials.gov) - Mar 22, 2019
P=N/A, N=257, Completed, Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Oct 2018 Recruiting --> Completed | N=375 --> 257 | Trial completion date: Jun 2021 --> May 2018 | Trial primary completion date: Jun 2019 --> May 2018
- |||||||||| Trial completion, Enrollment change, Trial completion date: Transperineal Ultrasound to Assess the Progress of Labour (clinicaltrials.gov) - Mar 21, 2019
P=N/A, N=297, Completed, Recruiting --> Completed | N=375 --> 257 | Trial completion date: Jun 2021 --> May 2018 | Trial primary completion date: Jun 2019 --> May 2018 Recruiting --> Completed | N=700 --> 297 | Trial completion date: Oct 2018 --> Jan 2018
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy (clinicaltrials.gov) - Mar 21, 2019
P=N/A, N=107, Completed, Recruiting --> Completed | N=700 --> 297 | Trial completion date: Oct 2018 --> Jan 2018 Recruiting --> Completed | N=180 --> 107 | Trial completion date: Feb 2020 --> Oct 2017 | Trial primary completion date: Feb 2020 --> Oct 2017
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Yoga Practice for Breast or Ovarian Cancer Patients (clinicaltrials.gov) - Mar 14, 2019
P=N/A, N=39, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2019 Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Mar 2019 | Trial primary completion date: Nov 2019 --> Mar 2019
- |||||||||| PD 360324 / Pfizer
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Mar 12, 2019 P2, N=0, Withdrawn, Active, not recruiting --> Completed N=15 --> 0 | Trial completion date: Dec 2020 --> Feb 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Feb 2019
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: PET CT With HX4 in Cervix Cancer (clinicaltrials.gov) - Mar 8, 2019
P2, N=4, Terminated, Active, not recruiting --> Completed | Phase classification: P1 --> PN/A N=20 --> 4 | Trial completion date: Nov 2016 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> May 2018; patients did not want to participate
|